| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/01/2009 | EP2042606A1 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic use |
| 04/01/2009 | EP2042605A1 Integration optimised viral vectors for gene therapy |
| 04/01/2009 | EP2042599A1 Method of making microencapsulated DNA for vaccination and gene therapy |
| 04/01/2009 | EP2042598A1 5T4 tumour-associated antigen for use in tumour immunotherapy |
| 04/01/2009 | EP2042510A2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) |
| 04/01/2009 | EP2042509A1 Modulators of the function of FAS receptors and other proteins |
| 04/01/2009 | EP2041171A2 Epitope-tag for surface-expressed proteins and uses thereof |
| 04/01/2009 | EP2040719A1 Use of cells derived from adipose tissue for the preparation of an anti-tumour medicament |
| 04/01/2009 | EP1549341B1 Tissue factor targeted antibodies as anticoagulants |
| 04/01/2009 | EP1472375B1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 04/01/2009 | EP1427825B1 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 04/01/2009 | EP1131087B2 Alleviatation of prostate cancer symptoms |
| 04/01/2009 | EP0970207B1 Heregulin variants |
| 04/01/2009 | CN101400791A De-differentiation of astrocytes into neural stem cell using NANOG |
| 04/01/2009 | CN101400697A Prevention/treatment of ichthyosis vulgaris, atopy and other disorders |
| 04/01/2009 | CN101400368A Cancer treatment using viruses, fluoropyrimidines and camptothecins |
| 04/01/2009 | CN101400366A Hepatitis c virus non structural fusion protein |
| 04/01/2009 | CN101397574A Flavivirus NS1 subunit vaccine |
| 04/01/2009 | CN101397573A Retroviral vector for expression of glial cell line-derived neurotrophic factor and use thereof |
| 04/01/2009 | CN101397572A Method for rescuing influenza virus and bidirectional transcription vector special therefor |
| 04/01/2009 | CN101397571A Preparation of double promoter DNA anti-caries vaccine pCN-SSIE |
| 04/01/2009 | CN101397564A Protection against environmental toxicity through manipulation of the processing of messenger RNA precursors |
| 04/01/2009 | CN101397558A Clone, expression and use of schistosoma japonicum membrane protein gene TSP2 |
| 04/01/2009 | CN101397551A Neukinase and its use in treatment of cardiovascular disease |
| 04/01/2009 | CN101397336A Antigenic Neisserial peptides |
| 04/01/2009 | CN101396564A Protein capable of adjusting sperm capacitation and use thereof |
| 04/01/2009 | CN101396556A Immunoregulation DNA vaccine capable of preventing chicken Eimeria maxima |
| 04/01/2009 | CN101396555A Methods and compositions for interferon therapy |
| 04/01/2009 | CN100473721C Pneumovirus NS proteins antagonising interferon (IFN) response |
| 04/01/2009 | CN100473417C Method of modulating memory effector T-cells using CD2-binding agent, and compositions |
| 03/31/2009 | US7511132 Short interfering RNA sequences for use in the treatment and prevention of diabetes, alzheimer's and cancer; gene expression inhibition |
| 03/31/2009 | US7511027 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold |
| 03/31/2009 | US7511017 Inhibiting apoptosis associated with HIV infection; immunoglobulin constant domain heterologous polypeptide; isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5 |
| 03/31/2009 | US7510875 Methods for producing purified adenoviral vectors |
| 03/31/2009 | US7510870 STAT3 activated stem cell |
| 03/31/2009 | US7510868 Chimeric adenoviruses for use in cancer treatment |
| 03/31/2009 | US7510855 Comprises nucleotide sequences coding protein of urogenital system for identifying moduators for treatment of cell proliferative and metastatic disorders |
| 03/31/2009 | US7510853 Exhibiting similarity to cytokine; isolated or recombinant polynucleotide encoding antigenic polypeptide of sequence 2 |
| 03/31/2009 | US7510835 Methods for identifying risk of breast cancer and treatments thereof |
| 03/31/2009 | US7510826 Process for the depletion or removal of endotoxins |
| 03/31/2009 | US7510718 Expression vector comprising nucleotide sequences coding multimeric nuclear anchoring-protein for use as tool in transfer, expression and propagation of heterologous gene sequences |
| 03/31/2009 | US7510708 Disruption of the REG pathway |
| 03/31/2009 | US7510706 Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity |
| 03/31/2009 | CA2494888C Substances for preventing and treating autoimmune diseases |
| 03/31/2009 | CA2066204C Cystic fibrosis gene |
| 03/26/2009 | WO2009039217A1 Medicaments for the treatment of coronary syndromes |
| 03/26/2009 | WO2009039198A2 Generation of hyperstable mrnas |
| 03/26/2009 | WO2009038756A2 Long interspersed nuclear element polypeptide compositions and methods of use thereof |
| 03/26/2009 | WO2009038266A1 Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv |
| 03/26/2009 | WO2009036574A1 Method of reducing the effects of cytostatic drugs on bone marrow derived cells, and methods of screening |
| 03/26/2009 | WO2009021034A3 Methods of treating b-cell cancers |
| 03/26/2009 | WO2005042702A3 Compositions of stabilized dna for coating microprojections |
| 03/26/2009 | WO2004104161A3 Methods and systems for identifying naturally occurring antisense transcripts and methods, kits and arrays utilizing same |
| 03/26/2009 | WO2004064612A3 Regulation of tgf-b signaling by tomoregulin |
| 03/26/2009 | US20090082717 Dermal micro-organs, methods and apparatuses for producing and using the same |
| 03/26/2009 | US20090082556 siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
| 03/26/2009 | US20090082302 Modulation of eif4e-bp2 expression |
| 03/26/2009 | US20090082300 Modulation of transthyretin expression |
| 03/26/2009 | US20090082298 Methods for producing microRNAs |
| 03/26/2009 | US20090082296 Mycobacterial antigens expressed during latency |
| 03/26/2009 | US20090082293 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| 03/26/2009 | US20090082292 inhibiting angiogenesis; corneal graft rejection; age related macular degeneration; diabetic retinopathy; dermatological disease |
| 03/26/2009 | US20090082291 Methods of treatment of acute renal failure |
| 03/26/2009 | US20090082289 Adenoviral vectors having a protein IX deletion |
| 03/26/2009 | US20090082274 Collections of repeat proteins comprising repeat modules |
| 03/26/2009 | US20090082250 Control of gene expression using a complex of an oligonucleotide and a regulatory peptide |
| 03/26/2009 | US20090081756 Nucleic acid-enzyme complex |
| 03/26/2009 | US20090081653 A nucleic acid regulating the expression of a gene responsive to insulin where the nucleic acid hybridizes under moderate stringency conditions to a hybridization probe; obesity; insulin-resistance syndrome; antidiabetic and -proliferative |
| 03/26/2009 | US20090081635 Modified heparinase iii and methods of sequencing therewith |
| 03/26/2009 | US20090081306 Microencapsulated materials and method of making same |
| 03/26/2009 | US20090081283 Tumor therapy with non-viral-based high affinitiy laminin receptor-targeted vectors |
| 03/26/2009 | US20090081274 Mast cell-derived renin |
| 03/26/2009 | US20090081241 comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein |
| 03/26/2009 | US20090081227 Promotong differentiation of neural stem cells to nerve cells for use in treating injury to central nerve system caused by brain infarction, hemorrhage and/or spinal cord injury |
| 03/26/2009 | US20090081215 Genetic products differentially expressed in tumors and use thereof |
| 03/26/2009 | US20090081214 Genetic products differentially expressed in tumors and use thereof |
| 03/26/2009 | US20090081183 HIV Transcription Repressor Complex and Compositions and Methods Based Thereon |
| 03/26/2009 | US20090081131 Tumor therapy with high affinity laminin receptor-targeted vectors and compounds |
| 03/26/2009 | CA2711818A1 Method of reducing the effects of cytostatic drugs on bone marrow derived cells, and methods of screening |
| 03/25/2009 | EP2039773A1 Mutant vesicular stomatitis viruses and use thereof |
| 03/25/2009 | EP2039768A1 Mutant forms of Fas ligand and uses thereof |
| 03/25/2009 | EP2039367A1 Prophylactic/therapeutic agent for neurodegenerative disease |
| 03/25/2009 | EP2039251A1 Methods for generating genetically altered antibody-producing cell lines with improved antibody characteristics |
| 03/25/2009 | EP2038415A1 Dph2 gene deletion mutant and uses thereof |
| 03/25/2009 | EP2037943A2 Treatment of connective tissue disorders |
| 03/25/2009 | EP1945266A4 Methods of modulating apoptosis and platelet production using variants of cytochrome c |
| 03/25/2009 | EP1879624A4 Gene therapy for neurometabolic disorders |
| 03/25/2009 | EP1242587B1 A NOVEL ISOFORM OF HUMAN cAMP-DEPENDENT PROTEIN KINASE, C ALPHA-s, LOCALIZES TO SPERM MIDPIECE AND THE USE THEREOF |
| 03/25/2009 | EP0960197B1 GENES FROM 20q13 AMPLICON AND THEIR USES |
| 03/25/2009 | CN101395168A Galactose derivative,Drug carrier and medicinal composition |
| 03/25/2009 | CN101394868A Strong immune induction by using combination of adenovirus type-5/type-35 vector and vaccinia virus mva vector |
| 03/25/2009 | CN101392267A Therapeutic effects of Math1 gene pairs forsensorineural hearing loss |
| 03/25/2009 | CN101392261A Modified highly pathogenic porcine reproductive and respiratory syndrome virus ORF5 gene and application |
| 03/25/2009 | CN101392251A Micro RNA capable of inducing stem cell to differentiate toward osteoblasts and use thereof |
| 03/25/2009 | CN101391105A Gene therapy for critical limb ischemia with wild type or mutant eNOS |
| 03/25/2009 | CN101391104A New use of oncolytic adenovirus recombinant of tumour cell single-expression immunoloregulation fator GM-CSF |
| 03/25/2009 | CN100471957C Adenovirus vectors for immunotherapy |
| 03/25/2009 | CN100471951C Method of diagnosing genotype of nucleic acid sample |
| 03/25/2009 | CN100471868C Compositions and methods for WT1 specific immunotherapy |
| 03/25/2009 | CN100471862C Antisense oligonucleotides that inhibit expression of HIF-1 |